Preoperative monocyte-to-lymphocyte ratio as a potential predictor of bladder cancer
Author:
Napolitano Luigi1, Barone Biagio1ORCID, Reccia Pasquale1, De Luca Luigi1, Morra Simone1, Turco Carmine1, Melchionna Alberto1, Morgera Vincenzo1, Cirillo Luigi1, Fusco Giovanni Maria1, Mirto Benito Fabio1, Napodano Giorgio2, Del Biondo Dario2, Prezioso Domenico1, Imbimbo Ciro1, Crocetto Felice1
Affiliation:
1. Department of Neurosciences, Reproductive Sciences and Odontostomatology , University of Naples “Federico II” , Naples , Italy 2. Department of Urology , Ospedale del Mare, ASL Napoli 1 Centro , Naples , Italy
Abstract
Abstract
Objectives
The aim of this study was to investigate the role of preoperative Monocyte-to-Lymphocyte ratio (MLR) as a potential predictor of bladder cancer (BC).
Methods
Clinical data of patients who underwent TURBT at our institution between 2017 and 2021 were collected and retrospectively analysed. MLR was obtained from preoperative blood analyses performed within 1 month from hospital admission. The association of MLR with different clinic-pathological features obtained from histological reports was further analysed. Statistical analysis was performed using the Kruskal Wallis test for non-parametric variables, assuming p<0.05 as statistically significant.
Results
510 patients were included in the study (81% males, 19% females), with a mean age of 71.66 ± 11.64 years. Mean MLR was higher in patients with any-type bladder cancer, reporting an MLR of 0.41 ± 0.11 compared to 0.38 ± 0.43 in patients without bladder cancer (p=0.043). In the subsequent comparison among low-grade and high-grade bladder cancer, MLR did not report statistically significant differences, with 0.29 ± 0.12 for low-grade BC and 0.51 ± 0.81 for high-grade BC (p=0.085)
Conclusions
Our findings reported elevated preoperative MLR should be considered a potential biomarker predicting malignancy for bladder tumours. Furthermore, research are necessary to assess its role in discerning low-grade from high-grade patients.
Publisher
Walter de Gruyter GmbH
Subject
Drug Discovery,Pharmacology,General Medicine,Physiology
Reference42 articles.
1. Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. https://doi.org/10.3322/caac.21492. 2. Ferlay, J, Colombet, M, Soerjomataram, I, Parkin, DM, Piñeros, M, Znaor, A, et al.. Cancer statistics for the year 2020: an overview. Int J Cancer 2021;149:778–89. https://doi.org/10.1002/ijc.33588. 3. Saginala, K, Barsouk, A, Aluru, JS, Rawla, P, Padala, SA, Barsouk, A. Epidemiology of bladder cancer. Med Sci 2020;8:E15. https://doi.org/10.3390/medsci8010015. 4. Klaile, Y, Schlack, K, Boegemann, M, Steinestel, J, Schrader, AJ, Krabbe, LM. Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease? Transl Androl Urol 2016;5:692–701. https://doi.org/10.21037/tau.2016.06.13. 5. Zhu, S, Yu, W, Yang, X, Wu, C, Cheng, F. Traditional classification and novel subtyping systems for bladder cancer. Front Oncol 2020;10:102. https://doi.org/10.3389/fonc.2020.00102.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|